EMERYVILLE, CA / ACCESSWIRE / April 21, 2015 / NovaBay(R) Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company commercializing and developing non-antibiotic antimicrobial products for the global eye care market, today announced that the registration statement on Form S-3 associated with the Company's March 2015 private placement has been declared effective by the U.S. Securities and Exchange Commission (SEC).
The registration of these shares causes them to be eligible for open trading in the stock market. The registration statement on Form S-3 and Notice of Effectiveness may be accessed through the SEC's website at http://www.sec.gov. Although the registration of these shares increases the number of shares available on the open market, it is does affect the daily operations of the Company.
About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics(R)
NovaBay Pharmaceuticals is a biopharmaceutical company focusing commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: the NEUTROX(TM) Family of Products, including AVENOVA(TM) for the eye care market and NEUTROPHASE(R) for wound care, which was initially cleared by FDA, and CELLERX(TM) for the dermatology market; and its AGANOCIDE(R) compounds, led by AURICLOSENE(TM). NovaBay is partnered in the U.S. and around the globe with: PBE, Inc. (USA), IHT, Inc. (USA), Galderma (France), Virbac (France), China Pioneer Pharma (China and Southeast Asia), Shin Poong Pharmaceuticals (South Korea), Biopharm (North African and Middle East), Sarmedic Ltd (Israel) and Alpha Pharma LLC (Ukraine).
Forward-Looking Statements
This press release may contain forward-looking statements, which speak only as of the date of this release and are based on current expectations and involve a number of assumptions. All such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts. The Company intends all forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and is including this statement for purposes of these safe harbor provisions. More information about the Company and its capitalization can be found in our recently filed 10-K and other SEC filings. Lastly, the Company undertake no obligation to update or clarify these forward-looking statements, whether as a result of new information, future events or otherwise.
Stay informed on NovaBay's progress:
Like us on Facebook
Follow us on Twitter
Connect with NovaBay on LinkedIn
Join us on Google+
Visit NovaBay's Website
NovaBay Contacts
For NovaBay Avenova purchasing information, please contact:
Email us
Call us: 1-800-890-0329
www.Avenova.com
From the Company
Thomas J. Paulson
Chief Financial Officer
510-899-8809
Contact Tom
Investor Contact
LHA
Jody Cain
310-691-7100
Jcain@lhai.com
SOURCE: NovaBay Pharmaceuticals, Inc.
